Summary
This prediction ended on 06.09.18 with a price of €77.62. The prediction for Bayer AG disappointed with a performance of -28.07%. gerihouse has 50% into this predictionBayer is a multinational pharmaceutical and life sciences company headquartered in Germany. The company was founded in 1863 and has since grown to become a global leader in the fields of pharmaceuticals, agriculture, and consumer health. Bayer is listed on the Frankfurt Stock Exchange and also trades over-the-counter in the United States under the ticker symbol BAYZF. The company's products include prescription drugs, over-the-counter medicines, and agrochemicals, and it operates in more than 90 countries around the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Bayer AG | -4.878% | -4.878% | -57.344% | -51.498% |
| iShares Core DAX® | -1.785% | -1.250% | 11.664% | 12.714% |
| iShares Nasdaq 100 | -2.154% | 0.300% | 37.531% | 41.653% |
| iShares Nikkei 225® | -4.028% | -3.746% | 17.142% | 0.393% |
| iShares S&P 500 | -1.969% | 0.307% | 25.617% | 40.084% |
According to gerihouse what are the pros and cons of Bayer AG for the foreseeable future?
Pros
Cons
Comments by gerihouse for this prediction
In the thread Bayer AG diskutieren
Attraktiv
Luisa Hector, Analystin von Exane BNP Paribas, rät in einer aktuellen Aktienanalyse zum Kauf der Aktie des Chemie- und Pharmakonzerns Bayer AG und erhöht das Kursziel
von 103 auf 130 Euro.
Der Leverkusener Konzern biete nach der angestrebten Übernahme des US-Saatgutherstellers Monsanto die seltene Möglichkeit, auf die Segmente Pharma und Pflanzenschutz zu setzen, so
die Analystin in einer heute veröffentlichten Studie. Dabei sehe Hector beide Geschäftsbereiche vor einem Aufschwung. Die Bayer-Aktie sei historisch gesehen und auch im Branchenvergleich attraktiv bewertet.
